PSUSA/00001232/202507

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 20-23 April 2026

List of medicines currently in PRIME scheme

Human medicines European public assessment report (EPAR): Olanzapine Glenmark Europe, olanzapine, Date of authorisation: 03/12/2009, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Olanzapine Glenmark, olanzapine, Date of authorisation: 03/12/2009, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Elebrato Ellipta, fluticasone furoate,umeclidinium,vilanterol, Date of authorisation: 15/11/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Trelegy Ellipta, fluticasone furoate,umeclidinium,vilanterol, Date of authorisation: 15/11/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Remsima, infliximab, Date of authorisation: 10/09/2013, Revision: 48, Status: Authorised

PSUSA/00002434/202508

PSUSA/00000448/202508